Pura Vida Investments’s Travere Therapeutics TVTX Stock Holding History

Pura Vida Investments’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-166,201	Closed	-$4.03M	–	254
2022 Q2	$4.03M	Buy	166,201 +55,976	+51%	+$1.41M	0.23%	101
2022 Q1	$2.84M	Buy	110,225 +300	+0.3%	+$7.96K	0.09%	148
2021 Q4	$3.41M	Buy	109,925 +56,135	+104%	+$1.58M	0.12%	128
2021 Q3	$1.3M	Sell	53,790 -51,592	-49%	-$948K	0.04%	208
2021 Q2	$1.54M	Sell	105,382 -21,151	-17%	-$417K	0.05%	165
2021 Q1	$3.16M	Buy	+126,533	New	+$3.5M	0.09%	141

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pura Vida Investments's TVTX Position: Q3 2022 in Review

Pura Vida Investments sold out of Travere Therapeutics (TVTX) in Q3 2022, closing a stake of 166,201 shares — an estimated $4.03M sold.

Pura Vida Investments first reported a position in TVTX in Q1 2021 and held it in 6 quarters. The position peaked at $4.03M in Q2 2022. 171 funds tracked by Wall St. Rank hold TVTX as of Q3 2022.

Pura Vida Investments reported no remaining Travere Therapeutics position as of Q3 2022 after selling out during the quarter.
Pura Vida Investments sold 166,201 Travere Therapeutics shares in Q3 2022, an estimated $4.03M.
Pura Vida Investments first reported a position in Travere Therapeutics in Q1 2021 and held it in 6 quarters.
Pura Vida Investments's Travere Therapeutics position peaked at $4.03M in Q2 2022.
171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2022.

Based on Pura Vida Investments's 13F filing for Q3 2022, filed 14 Nov 2022.